LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Apellis Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

19.28 1.21

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.06

Максимум

19.69

Ключови измерители

By Trading Economics

Приходи

-56M

-92M

Продажби

-46M

167M

EPS

-0.74

Марж на печалбата

-55.292

Служители

705

EBITDA

-56M

-80M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+83.97% upside

Дивиденти

By Dow Jones

Следващи печалби

31.07.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-191M

2.4B

Предишно отваряне

18.07

Предишно затваряне

19.28

Настроения в новините

By Acuity

84%

16%

361 / 380 Класиране в Healthcare

Apellis Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.06.2025 г., 14:31 ч. UTC

Печалби

New York State Retirement Fund Posts 5.84% Annual Investment Return

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 20:33 ч. UTC

Печалби

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 19:36 ч. UTC

Пазарно говорене

Oil Futures Post Solid Weekly Gains -- Market Talk

6.06.2025 г., 19:28 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6.06.2025 г., 18:46 ч. UTC

Пазарно говорене

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6.06.2025 г., 18:02 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Continues to Decline -- Market Talk

6.06.2025 г., 16:35 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:34 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6.06.2025 г., 16:21 ч. UTC

Пазарно говорене

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

6.06.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.06.2025 г., 16:07 ч. UTC

Пазарно говорене

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6.06.2025 г., 15:53 ч. UTC

Пазарно говорене

Mexican Inflation Seen Rising in May -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6.06.2025 г., 15:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 15:33 ч. UTC

Пазарно говорене

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6.06.2025 г., 15:16 ч. UTC

Пазарно говорене

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6.06.2025 г., 15:05 ч. UTC

Пазарно говорене

Silver at its Highest In Nearly 15 Years -- Market Talk

6.06.2025 г., 14:35 ч. UTC

Пазарно говорене

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.06.2025 г., 14:28 ч. UTC

Пазарно говорене

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6.06.2025 г., 14:15 ч. UTC

Пазарно говорене

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6.06.2025 г., 14:12 ч. UTC

Печалби

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6.06.2025 г., 14:09 ч. UTC

Печалби

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Apellis Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

83.97% нагоре

12-месечна прогноза

Среден 35.47 USD  83.97%

Висок 57 USD

Нисък 18 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Apellis Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

19 ratings

11

Купи

8

Задържане

0

Продай

Настроение

By Acuity

361 / 380 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.